Quantitative and qualitative alteration in intracellular cholesterol status regulates statin sensitivity in non-small-cell lung cancer cells
Journal of Pharmacological Sciences · 2026-12 · 162 (4) · 268-280
DOI: 10.1016/j.jphs.2026.09.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacological Sciences, 2026-12. Verfasst von Jiro Tashiro und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Basic Veterinary Science, Joint Graduate School of Veterinary Sciences, Tottori University, Tottori, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cholesterol, Lung Neoplasms, Atorvastatin. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Support for Pioneering Research Initiated by the Next Generation, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Non-small-cell lung cancer (NSCLC) is a major type of lung cancer, accounting for 85% of lung cancer cases. Statins are cholesterol-lowering drugs that exert anticancer effects by inhibiting HMG-CoA reductase (HMGCR), a rate-limiting enzyme in the mevalonate pathway, in multiple cancer types, including NSCLC. However, statin sensitivity varies among cancer cells, highlighting the need to identify the determinants of this variability. High basal expression and statin-induced upregulation of mevalonate pathway enzymes, including HMGCR, are associated with statin resistance in cancer cells. Given that the expression of mevalonate pathway enzymes is regulated by cholesterol, intracellular cholesterol status may influence statin sensitivity. Here, we demonstrated that cholesterol supplementation enhanced the growth-inhibitory effects of atorvastatin in NSCLC cells with an increase in fluorescence intensity of filipin, which binds to free cholesterol. In contrast, methyl-β-cyclodextrin, a cholesterol-depleting agent, attenuated the effects of atorvastatin with a slight decrease in filipin intensity. In addition, oxysterols, which are oxidized derivatives of cholesterol, enhanced the effects of atorvastatin without increasing the filipin intensity. Furthermore, the lysosomal cholesterol transport inhibitor U18666A attenuated the effects of atorvastatin, with an increase in filipin intensity. Our data suggested that quantitative and qualitative intracellular cholesterol status may regulate statin sensitivity in NSCLC cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Basic Veterinary Science, Joint Graduate School of Veterinary Sciences, Tottori University, Tottori, Japan.
- Department of Biomedical Sciences, School of Biological and Environmental Sciences, Kwansei Gakuin University, Hyogo, Japan.
- Division of Basic Veterinary Science, Joint Graduate School of Veterinary Sciences, Tottori University, Tottori, Japan. Electronic address: waritak@tottori-u.ac.jp.
Förderung
- Support for Pioneering Research Initiated by the Next Generation
- Japan Society for the Promotion of Science
Zitieren
APA
Tashiro, J., Warita, T., & Warita, K. (2026). Quantitative and qualitative alteration in intracellular cholesterol status regulates statin sensitivity in non-small-cell lung cancer cells. Journal of Pharmacological Sciences, 162(4), 268-280. https://doi.org/10.1016/j.jphs.2026.09.005
Vancouver
Tashiro J, Warita T, Warita K. Quantitative and qualitative alteration in intracellular cholesterol status regulates statin sensitivity in non-small-cell lung cancer cells. Journal of Pharmacological Sciences. 2026;162(4):268-280. doi:10.1016/j.jphs.2026.09.005
BibTeX
@article{Tashiro2026,
author = {Tashiro, Jiro and Warita, Tomoko and Warita, Katsuhiko},
title = {Quantitative and qualitative alteration in intracellular cholesterol status regulates statin sensitivity in non-small-cell lung cancer cells},
journal = {Journal of Pharmacological Sciences},
year = {2026},
volume = {162},
number = {4},
pages = {268--280},
doi = {10.1016/j.jphs.2026.09.005}
}
EUVIMED